Immune response after SARS-CoV-2 vaccination in patients with inflammatory immune-mediated diseases receiving immunosuppressive treatment.

Chamaida Plasencia-RodriguezAna Martínez-FeitoMarta HernándezLucia Del Pino-MolinaMarta Novella-NavarroYolanda SerranoMiguel González-MuñozDiana PeiteadoGema BonillaIrene MonjoLaura NuñoCarolina TorneroEduardo López-GranadosAlejandro BalsaPilar Nozal

Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2023)

SARS-CoV-2 antibody levels were lower in patients than in controls, especially in patients treated with rituximab. A cellular response can be detected despite having a poor humoral response. Severe infections in vaccinated patients with IMIDs are rare, and are observed mainly in patients treated with rituximab.

Keyphrases

sars cov
immune response
end stage renal disease
diffuse large b cell lymphoma
respiratory syndrome coronavirus
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
chronic lymphocytic leukemia
dendritic cells
toll like receptor
coronavirus disease
smoking cessation